Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
219580-11-7
Purity
95%
PD173074 is a potent FGFR inhibitor with an IC50s of 3nM for FGFR3 and FGFR2, and 3.6nM for FGFR1. It also inhibits VEGFR2.
Properties
Name
PD173074
Smiles
CCN(CC)CCCCNC=1N=CC=2C=C(C(NC(=O)NC(C)(C)C)=NC2N1)C=3C=C(OC)C=C(OC)C3
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
PD 173074
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$48
2 mg
$50
5 mg
$51
10 mg
$58
15 mg
$63
20 mg
$68
25 mg
$76
30 mg
$80
35 mg
$88
40 mg
$96
45 mg
$104
50 mg
$111
75 mg
$128
100 mg
$POA
Quantity
1
Total amount
$ 51
PD 173074
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.
PD173074 (CAS 219580-11-7), also known as PF-01367255, is a strong and selective blocker of fibroblast growth factor receptors (FGFRs). These receptor tyrosine kinases play an important role in regulating cell proliferation, differentiation, angiogenesis, and tissue repair. Because of its strong inhibitory activity, +PD173074 has become a widely used research compound in studies focused on oncogenic signaling pathways and targeted cancer therapies.
The compound is characterized by a defined molecular formula and reliable physicochemical properties suitable for experimental work in biochemical and cellular models. Scientists frequently buy 219580-11-7 as a reference molecule for studying FGFR-mediated signaling and evaluating new kinase inhibitors. Due to its well-characterized mechanism, PD173074 remains an important tool in pharmaceutical and academic research.
PD173074 is widely used in biomedical research exploring receptor tyrosine kinase signaling, especially pathways associated with fibroblast growth factor receptors. Inhibition of these pathways allows researchers to investigate mechanisms related to tumor growth, angiogenesis, and cellular communication.
In vitro studies demonstrate that PD173074 effectively inhibits FGFR kinase activity, blocking downstream signaling events within the MAPK and PI3K pathways. This inhibition suppresses cellular proliferation and alters signaling networks involved in tumor development. Researchers frequently use PD173074 in cultured cancer cell lines to analyze pathway inhibition and evaluate the biological effects of FGFR blockade.
In vivo experiments have shown that inhibition of FGFR signaling by PD173074 can influence tumor growth and angiogenesis in preclinical models. These studies help researchers understand how FGFR-driven signaling contributes to cancer progression and how targeted inhibitors may affect disease outcomes.
The biochemical activity of PD173074 is based on its selective interaction with FGFR kinase domains, preventing receptor autophosphorylation and downstream signal transduction. By interrupting these pathways, the compound influences cellular proliferation, differentiation, and survival mechanisms associated with growth factor signaling.
PD173074 is widely used in laboratory research due to its selective inhibitory activity and well-characterized biological effects.
Access to validated bioactive molecules is essential for modern biomedical research. Scientists in pharmaceutical, biotechnology, and academic laboratories rely on high-quality compounds to investigate molecular targets, accelerate screening programs, and support the development of new therapeutic strategies.